CollPlant (CLGN) Biotechnologies announced the expansion of its European distribution network for Vergenix STR through the signing of a new agreement in Poland. Vergenix STR is based on the company’s rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLGN:
- CollPlant Biotechnologies Transfers Listing to Nasdaq Capital Market
- Promising Developments and Strategic Partnerships Justify Buy Rating for Collplant Holdings Despite Financial Shortfalls
- CollPlant Biotechnologies: Q2 2025 Financial Results and Updates
- CollPlant Biotechnologies Advances Dermal Filler Program and Reports Q2 2025 Financial Results
- CLGN Upcoming Earnings Report: What to Expect?